» Articles » PMID: 33124449

Five-Year Cost-Effectiveness Modeling of Primary Care-Based, Nonmydriatic Automated Retinal Image Analysis Screening Among Low-Income Patients With Diabetes

Overview
Specialty Endocrinology
Date 2020 Oct 30
PMID 33124449
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Artificial intelligence-based technology systems offer an alternative solution for diabetic retinopathy (DR) screening compared with standard, in-office dilated eye examinations. We performed a cost-effectiveness analysis of Automated Retinal Image Analysis System (ARIAS)-based DR screening in a primary care medicine clinic that serves a low-income patient population.

Methods: A model-based, cost-effectiveness analysis of two DR screening systems was created utilizing data from a recent study comparing adherence rates to follow-up eye care among adults ages 18 or older with a clinical diagnosis of diabetes. In the study, the patients were prescreened with an ARIAS-based, nonmydriatic (undilated), point-of-care tool in the primary care setting and were compared with patients with diabetes who were referred for dilated retinal screening without prescreening, as is the current standard of care. Using a Markov model with microsimulation resulting in a total of 600 000 simulated patient experiences, we calculated the incremental cost-utility ratio (ICUR) of the two screening approaches, with regard to five-year cost-effectiveness of DR screening and treatment of vision-threatening DR.

Results: At five years, ARIAS-based screening showed similar utility as the standard of care screening systems. However, ARIAS reduced costs by 23.3%, with an ICUR of $258 721.81 comparing the current practice to ARIAS.

Conclusions: Primary care-based ARIAS DR screening is cost-effective when compared with standard of care screening methods.

Citing Articles

Autonomous Artificial Intelligence for Diabetic Eye Disease Testing Improves Access and Equity in the Pediatric and Adult Populations: The Johns Hopkins Medicine Experience.

Liu T, Wolf R Diabetes Spectr. 2025; 38(1):19-22.

PMID: 39959516 PMC: 11825398. DOI: 10.2337/dsi24-0016.


Cost-effectiveness of AI for pediatric diabetic eye exams from a health system perspective.

Ahmed M, Dai T, Channa R, Abramoff M, Lehmann H, Wolf R NPJ Digit Med. 2025; 8(1):3.

PMID: 39747639 PMC: 11697205. DOI: 10.1038/s41746-024-01382-4.


Enhancing diabetic retinopathy screening: Non-mydriatic fundus photography-assisted telemedicine for improved clinical management.

Szulborski K, Ramsey D World J Diabetes. 2024; 15(8):1820-1823.

PMID: 39192855 PMC: 11346096. DOI: 10.4239/wjd.v15.i8.1820.


Advances in Structural and Functional Retinal Imaging and Biomarkers for Early Detection of Diabetic Retinopathy.

Zhang Z, Deng C, Paulus Y Biomedicines. 2024; 12(7).

PMID: 39061979 PMC: 11274328. DOI: 10.3390/biomedicines12071405.


Artificial Intelligence Applications in Diabetic Retinopathy: What We Have Now and What to Expect in the Future.

Kong M, Song S Endocrinol Metab (Seoul). 2024; 39(3):416-424.

PMID: 38853435 PMC: 11220221. DOI: 10.3803/EnM.2023.1913.


References
1.
Kuo J, Liu J, Gibson E, Rao P, Margolis T, Wilson B . Factors Associated with Adherence to Screening Guidelines for Diabetic Retinopathy Among Low-Income Metropolitan Patients. Mo Med. 2020; 117(3):258-264. PMC: 7302017. View

2.
Milea D, Najjar R, Zhubo J, Ting D, Vasseneix C, Xu X . Artificial Intelligence to Detect Papilledema from Ocular Fundus Photographs. N Engl J Med. 2020; 382(18):1687-1695. DOI: 10.1056/NEJMoa1917130. View

3.
Wong T, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M . Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care. 2009; 32(12):2307-13. PMC: 2782996. DOI: 10.2337/dc09-0615. View

4.
Wells J, Glassman A, Ayala A, Jampol L, Bressler N, Bressler S . Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-9. PMC: 4877252. DOI: 10.1016/j.ophtha.2016.02.022. View

5.
Daskivich L, Vasquez C, Martinez Jr C, Tseng C, Mangione C . Implementation and Evaluation of a Large-Scale Teleretinal Diabetic Retinopathy Screening Program in the Los Angeles County Department of Health Services. JAMA Intern Med. 2017; 177(5):642-649. PMC: 5818774. DOI: 10.1001/jamainternmed.2017.0204. View